Summary
The primary objective of this study is to assess and compare the efficacy and safety of
sacituzumab govitecan-hzi versus treatment of physician's choice (TPC) in participants with
hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2-) negative
metastatic breast cancer (MBC).